secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibitor Therapeutics, Inc. (INTI)
CIK:        0001042418
Form:       8-K
Filed at:   2023-05-31T23:59:59+00:00
Accession:  0001493152-23-019651
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Director Michelle Yanez resigns; Michael Jerman appointed to Inhibitor Therapeutics Board
--------------------------------------------------------------------------------

- Michelle Yanez resigned from the Board effective May 24, 2023, to take a full-time CFO role elsewhere; no disagreement with the company.
- Michael Jerman, CPA, appointed as independent director and Chairman of the Audit Committee, effective May 24, 2023.
- Jerman brings experience as CFO of private equity-backed companies, former PwC director, and USAF captain; deemed a financial expert.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1042418/000149315223019651/0001493152-23-019651-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1042418/000149315223019651/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-019651

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer